Longboard Pharmaceuticals (LBPH) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LBPH Stock Forecast

Longboard Pharmaceuticals stock forecast is as follows: an average price target of $61.00 (represents a 2.06% upside from LBPH’s last price of $59.77) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.

LBPH Price Target

The average price target for Longboard Pharmaceuticals (LBPH) is $61.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $16.00. This represents a potential 2.06% upside from LBPH's last price of $59.77.

LBPH Analyst Ratings

Hold

According to 6 Wall Street analysts, Longboard Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for LBPH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 4 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Longboard Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 14, 2024	Kalpit Patel	B.Riley Financial	$60.00	$58.83	2.00%	0.38%
Sep 18, 2024	Patrick Trucchio	H.C. Wainwright	$80.00	$27.58	190.07%	33.85%
Sep 10, 2024	Joon Lee	Truist Financial	$60.00	$34.51	73.86%	0.38%
Sep 06, 2024	Joel Beatty	Robert W. Baird	$60.00	$33.89	77.04%	0.38%
Jul 01, 2024	Josh Schimmer	Cantor Fitzgerald	$90.00	$28.76	212.93%	50.58%
Jun 10, 2024	Kalpit Patel	B.Riley Financial	$36.00	$18.11	98.79%	-39.77%
Apr 30, 2024	Joel Beatty	Robert W. Baird	$36.00	$21.30	69.01%	-39.77%
Nov 11, 2022	-	Guggenheim	$16.00	$4.60	247.83%	-73.23%

Row per page

Go to

The latest Longboard Pharmaceuticals stock forecast, released on Oct 14, 2024 by Kalpit Patel from B.Riley Financial, set a price target of $60.00, which represents a 2.00% increase from the stock price at the time of the forecast ($58.83), and a 0.38% increase from LBPH last price ($59.77).

Longboard Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	4	7
Avg Price Target	-	$65.00	$60.29
Last Closing Price	$59.77	$59.77	$59.77
Upside/Downside	-100.00%	8.75%	0.87%

In the current month, the average price target of Longboard Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Longboard Pharmaceuticals's last price of $59.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 15, 2024	H.C. Wainwright	Buy	Neutral	Downgrade
Oct 14, 2024	Wedbush	Outperform	Neutral	Downgrade
Oct 14, 2024	B. Riley	Buy	Neutral	Downgrade
Oct 14, 2024	Cantor Fitzgerald	Overweight	Neutral	Downgrade
Sep 18, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 05, 2024	B. Riley	Buy	Buy	Hold
Jul 02, 2024	Citigroup	Buy	Buy	Hold
Jul 01, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Jun 11, 2024	Citigroup	Buy	Buy	Hold
May 03, 2024	Wedbush	Outperform	Outperform	Hold

Row per page

Go to

Longboard Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company Downgrade its LBPH rating from "Buy" to "Neutral".

Longboard Pharmaceuticals Financial Forecast

Longboard Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	$3.00M	-
High Forecast	-	-	-	-	-	$3.00M	-
Low Forecast	-	-	-	-	-	$3.00M	-
# Analysts	-	-	-	-	-	5	-
Surprise %	-	-	-	-	-	-	-

Longboard Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LBPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Longboard Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	5	-
EBITDA	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

undefined analysts predict LBPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Longboard Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Longboard Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	5	-
Net Income	-	-	-	-	-	-	-
Avg Forecast	$-28.21M	$-27.50M	$-27.58M	$-26.57M	$-24.43M	$-22.54M	$-17.13M
High Forecast	$-28.21M	$-27.50M	$-27.58M	$-25.03M	$-23.67M	$-22.54M	$-17.13M
Low Forecast	$-28.21M	$-27.50M	$-27.58M	$-28.11M	$-24.81M	$-22.54M	$-17.13M
Surprise %	-	-	-	-	-	-	-

Longboard Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LBPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Longboard Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	5	-
SG&A	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Longboard Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LBPH last annual SG&A of $NaN (undefined).

Longboard Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	5	-
EPS	-	-	-	-	-	-	-
Avg Forecast	$-0.72	$-0.71	$-0.71	$-0.68	$-0.63	$-0.58	$-0.44
High Forecast	$-0.72	$-0.71	$-0.71	$-0.64	$-0.61	$-0.58	$-0.44
Low Forecast	$-0.72	$-0.71	$-0.71	$-0.72	$-0.64	$-0.58	$-0.44
Surprise %	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Longboard Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LBPH previous annual EPS of $NaN (undefined).

Longboard Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SNSE	Sensei Biotherapeutics	$0.50	$5.50	1000.00%	Buy
HOWL	Werewolf Therapeutics	$1.64	$12.00	631.71%	Buy
MOLN	Molecular Partners	$5.20	$29.00	457.69%	Buy
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
TIL	Instil Bio	$23.36	$78.25	234.97%	Hold
CCCC	C4 Therapeutics	$4.05	$13.50	233.33%	Buy
STOK	Stoke Therapeutics	$11.31	$30.60	170.56%	Buy
NUVB	Nuvation Bio	$2.58	$6.75	161.63%	Buy
CELC	Celcuity	$12.78	$31.50	146.48%	Buy
ASMB	Assembly Biosciences	$15.02	$35.50	136.35%	Buy
NXTC	NextCure	$1.30	$3.00	130.77%	Buy
DSGN	Design Therapeutics	$5.48	$9.67	76.46%	Buy
EWTX	Edgewise Therapeutics	$31.95	$45.00	40.85%	Buy
GRPH	LENZ Therapeutics	$3.18	$4.00	25.79%	Hold
LBPH	Longboard Pharmaceuticals	$59.77	$61.00	2.06%	Hold
IKNA	Ikena Oncology	$1.70	$1.33	-21.76%	Buy
CYT	Cyteir Therapeutics	$3.02	$2.00	-33.77%	Sell

LBPH Forecast FAQ

Is Longboard Pharmaceuticals a good buy?

No, according to 6 Wall Street analysts, Longboard Pharmaceuticals (LBPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of LBPH's total ratings.

What is LBPH's price target?

Longboard Pharmaceuticals (LBPH) average price target is $61 with a range of $16 to $90, implying a 2.06% from its last price of $59.77. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Longboard Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for LBPH stock, the company can go up by 2.06% (from the last price of $59.77 to the average price target of $61), up by 50.58% based on the highest stock price target, and down by -73.23% based on the lowest stock price target.

Can Longboard Pharmaceuticals stock reach $90?

LBPH's average twelve months analyst stock price target of $61 does not support the claim that Longboard Pharmaceuticals can reach $90 in the near future.

What are Longboard Pharmaceuticals's analysts' financial forecasts?

Longboard Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3M (high $3M, low $3M), average EBITDA is $0 (high $0, low $0), average net income is $-64.101M (high $-63.338M, low $-64.483M), average SG&A $0 (high $0, low $0), and average EPS is $-1.646 (high $-1.627, low $-1.656). LBPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-110M (high $-108M, low $-111M), average SG&A $0 (high $0, low $0), and average EPS is $-2.82 (high $-2.78, low $-2.86).